NME1
Basic information
Region (hg38): 17:51153559-51162428
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the NME1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 1 | |||||
missense | 2 | |||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 4 | |||||
Total | 0 | 0 | 1 | 2 | 4 |
Variants in NME1
This is a list of pathogenic ClinVar variants found in the NME1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
17-51154262-C-G | not specified | Benign (Jan 24, 2024) | ||
17-51154266-G-A | not specified | Benign (Jan 24, 2024) | ||
17-51154423-CT-C | Uncertain significance (-) | |||
17-51155675-C-A | NME1-NME2-related disorder | Likely benign (Aug 14, 2019) | ||
17-51161282-T-G | NME1-NME2-related disorder | Benign (May 14, 2018) | ||
17-51161675-C-A | not specified | Benign (Jan 24, 2024) | ||
17-51161814-C-T | not specified | Likely benign (Jul 19, 2023) | ||
17-51161838-A-G | not specified | Uncertain significance (Jul 06, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
NME1 | protein_coding | protein_coding | ENST00000336097 | 5 | 8893 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00318 | 0.835 | 125739 | 0 | 9 | 125748 | 0.0000358 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.537 | 92 | 108 | 0.854 | 0.00000670 | 1155 |
Missense in Polyphen | 22 | 33.924 | 0.64851 | 424 | ||
Synonymous | 0.342 | 37 | 39.7 | 0.931 | 0.00000247 | 339 |
Loss of Function | 1.16 | 5 | 8.70 | 0.575 | 4.56e-7 | 96 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000309 | 0.0000309 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000548 | 0.0000544 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000357 | 0.0000352 |
Middle Eastern | 0.0000548 | 0.0000544 |
South Asian | 0.0000653 | 0.0000653 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Major role in the synthesis of nucleoside triphosphates other than ATP. The ATP gamma phosphate is transferred to the NDP beta phosphate via a ping-pong mechanism, using a phosphorylated active-site intermediate. Possesses nucleoside-diphosphate kinase, serine/threonine-specific protein kinase, geranyl and farnesyl pyrophosphate kinase, histidine protein kinase and 3'-5' exonuclease activities. Involved in cell proliferation, differentiation and development, signal transduction, G protein- coupled receptor endocytosis, and gene expression. Required for neural development including neural patterning and cell fate determination. During GZMA-mediated cell death, works in concert with TREX1. NME1 nicks one strand of DNA and TREX1 removes bases from the free 3' end to enhance DNA damage and prevent DNA end reannealing and rapid repair. {ECO:0000269|PubMed:12628186, ECO:0000269|PubMed:16818237, ECO:0000269|PubMed:8810265}.;
- Pathway
- Pyrimidine metabolism - Homo sapiens (human);Drug metabolism - other enzymes - Homo sapiens (human);Purine metabolism - Homo sapiens (human);Tenofovir/Adefovir Pathway, Pharmacodynamics;Tenofovir/Adefovir Pathway, Pharmacokinetics;Zidovudine Pathway, Pharmacokinetics/Pharmacodynamics;Lamivudine Pathway, Pharmacokinetics/Pharmacodynamics;Abacavir Pathway, Pharmacokinetics/Pharmacodynamics;Adefovir Dipivoxil Metabolism Pathway;Tenofovir Metabolism Pathway;Gemcitabine Action Pathway;Lamivudine Metabolism Pathway;Gemcitabine Metabolism Pathway;Pyrimidine metabolism;pyrimidine deoxyribonucleotides <i>de novo</i> biosynthesis;UTP and CTP <i>de novo</i> biosynthesis;granzyme a mediated apoptosis pathway;endocytotic role of ndk phosphins and dynamin;Metabolism of nucleotides;Folate metabolism;purine deoxyribonucleosides salvage;Interconversion of nucleotide di- and triphosphates;Purine metabolism;Metabolism;Pyrimidine metabolism;superpathway of pyrimidine ribonucleotides <i>de novo</i> biosynthesis;superpathway of pyrimidine deoxyribonucleoside salvage;TGF_beta_Receptor;Purine nucleotides nucleosides metabolism;CMP phosphorylation;superpathway of purine nucleotide salvage;Pyrimidine nucleotides nucleosides metabolism;Posttranslational regulation of adherens junction stability and dissassembly;pyrimidine deoxyribonucleotide phosphorylation;superpathway of pyrimidine deoxyribonucleotides <i>de novo</i> biosynthesis;pyrimidine deoxyribonucleotides biosynthesis from CTP;Arf6 trafficking events;guanosine deoxyribonucleotides <i>de novo</i> biosynthesis;guanosine nucleotides <i>de novo</i> biosynthesis;adenosine deoxyribonucleotides <i>de novo</i> biosynthesis;guanosine ribonucleotides <i>de novo</i> biosynthesis;purine nucleotides <i>de novo</i> biosynthesis;Regulation of CDC42 activity;Validated targets of C-MYC transcriptional activation;Arf6 downstream pathway;E-cadherin signaling in the nascent adherens junction
(Consensus)
Recessive Scores
- pRec
- 0.461
Intolerance Scores
- loftool
- 0.866
- rvis_EVS
- -0.12
- rvis_percentile_EVS
- 44.54
Haploinsufficiency Scores
- pHI
- hipred
- Y
- hipred_score
- 0.506
- ghis
- 0.464
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.933
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Low | Low |
Primary Immunodeficiency | Medium | Low | Medium |
Cancer | Medium | Low | Medium |
Mouse Genome Informatics
- Gene name
- Nme1
- Phenotype
- liver/biliary system phenotype; neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype;
Gene ontology
- Biological process
- negative regulation of myeloid leukocyte differentiation;nucleoside diphosphate phosphorylation;GTP biosynthetic process;UTP biosynthetic process;CTP biosynthetic process;DNA metabolic process;endocytosis;lactation;negative regulation of cell population proliferation;negative regulation of gene expression;positive regulation of neuron projection development;response to amine;nucleobase-containing small molecule interconversion;hippocampus development;response to testosterone;cellular response to drug;regulation of apoptotic process;positive regulation of DNA binding;positive regulation of epithelial cell proliferation;response to cAMP;cellular response to glucose stimulus;cellular response to fatty acid
- Cellular component
- nucleus;cytoplasm;mitochondrial outer membrane;centrosome;cytosol;intermediate filament;membrane;ruffle membrane;myelin sheath;perinuclear region of cytoplasm;extracellular exosome
- Molecular function
- magnesium ion binding;RNA polymerase II regulatory region sequence-specific DNA binding;single-stranded DNA binding;RNA binding;deoxyribonuclease activity;nucleoside diphosphate kinase activity;protein binding;ATP binding;GTP binding;intermediate filament binding;enzyme binding;identical protein binding;gamma-tubulin binding;ribosomal small subunit binding